Egypt Anti-Hypertensive Drugs Market is expected to be dominated by Calcium Channel Blockers through 2028
Growing prevalence of hypertension is expected to drive
the growth of the Egypt anti-hypertensive drugs market during the forecast
period, 2024-2028.
According to TechSci
Research report, “Egypt Anti-Hypertensive Drugs - By Region, Competition, Forecast and Opportunities, 2018-2028”, the Egypt anti-hypertensive drugs
market is anticipated to expand at a remarkable rate during the projected
period, 2024–2028, owing to the rising prevalence of hypertension, increasing healthcare
spending, and the growing adoption of telemedicine. However, the market also
faces several challenges, including the high cost of some anti-hypertensive
drugs, low levels of awareness of hypertension, and the limited availability of
healthcare professionals in some parts of the country. To address these
challenges, the market is likely to see continued investment in education and
awareness campaigns, the development of more affordable and effective anti-hypertensive
drugs, and the expansion of telemedicine services. Other trends that are
expected to support the growth of the market include the use of digital health
technologies, the development of personalized treatment plans, and the
increasing focus on preventative healthcare. Thus, the Egypt anti-hypertensive
drugs market is poised for continued growth in the coming years, driven by both
demographic and technological factors, and with the potential to improve the
health outcomes of millions of Egyptians.
The COVID-19 pandemic
has a significant impact on the Egypt anti-hypertensive drugs market. While the
pandemic has led to increased awareness of the importance of managing
hypertension, it has also presented several challenges, such as disruptions to
supply chains, reduced access to healthcare services, and financial constraints
among patients. As a result, the market has seen both opportunities and
challenges emerge. On the one hand, the growing adoption of telemedicine and
digital health technologies has enabled remote monitoring and management of
hypertension, which is likely to support the growth of the market. On the other
hand, the economic impact of the pandemic has created financial pressures for
patients and healthcare systems, which may limit their ability to access and
afford anti-hypertensive drugs.
Browse over 30 market
data Figures spread through 70 Pages and an in-depth TOC on "Egypt Anti-Hypertensive Drugs Market"
The Egypt anti-hypertensive
drugs market can be segmented by therapeutic class, type, distribution channel,
and region.
Based on type,
the market can be segmented into primary hypertension and secondary
hypertension. Primary hypertension, also known as essential hypertension, is
expected to dominate the Egypt anti-hypertensive drugs market in the coming
years due to its high prevalence and the lack of a known underlying cause. As
the population of Egypt continues to age and adopt unhealthy lifestyles, the
prevalence of primary hypertension is likely to increase. This, in turn, will
drive the demand for antihypertensive drugs, which are the mainstay of
treatment for primary hypertension. The availability of affordable and
effective antihypertensive drugs will be crucial to managing this growing
burden of disease and reducing the risk of complications associated with
hypertension. Therefore, primary hypertension is expected to remain the primary
focus of the Egypt anti-hypertensive drugs market during the forecast period.
In
terms of therapeutic class, the market can be divided into diuretics, ACE
inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, beta
adrenergic blockers, renin inhibitors, vasodilators, and others. Calcium
channel blockers (CCBs) are expected to dominate the Egypt anti-hypertensive
drugs market in the coming years due to their efficacy, safety, and relatively
low cost. CCBs are widely used as first-line treatment for hypertension and are
recommended by international guidelines as a preferred medication for the
elderly and in patients with coexisting conditions, such as diabetes or heart
failure. In Egypt, the aging population and the increasing burden of chronic
diseases are likely to drive the demand for CCBs. In addition, the availability
of affordable generic versions of CCBs is expected to further boost their
market dominance. Furthermore, ongoing research in the development of new CCBs
with improved safety and efficacy profiles is likely to strengthen their
position in the market.
Major companies
operating in Egypt anti-hypertensive drugs market include:
- Amoun Pharmaceutical Company
- EIPICO (Egyptian International
Pharmaceutical Industries Co.)
- Delta Pharma
- Rameda Pharmaceutical Company
- El-Nasr Pharmaceutical Chemicals Company
- Egyphar
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“The Egypt anti-hypertensive
drugs market is expected to grow steadily in the coming years due to several
factors, including the growing prevalence of hypertension, the increasing
adoption of telemedicine, and the availability of affordable and effective
medications. However, the market faces several challenges, such as the high
cost of drug development, the need for ongoing clinical trials to demonstrate
safety and efficacy, and the threat of patent expirations and generic
competition. Nevertheless, ongoing technological advancements, such as the
development of new drug delivery systems, are expected to drive innovation and
enhance the market's growth potential. Additionally, emerging trends, such as
personalized medicines and the use of digital health technologies, are expected
to further transform the management of hypertension and the anti-hypertensive
drugs market,” said Mr. Karan Chechi, Research Director with TechSci Research,
a research-based global management consulting firm.
“Egypt
Anti-Hypertensive Drugs Market, By Therapeutic Class (Diuretics, ACE
inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers,
Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type
(Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail
Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores), By
Region, Competition, Forecast & Opportunities, 2028”, has evaluated the future
growth potential of the Egypt anti-hypertensive drugs market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the Egypt anti-hypertensive drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com